One-Week versus Two-Week Chemoradiotherapy Followed by Curative Surgery in Rectal Cancer: Long-Term Comparative Pooled Analysis of Two Prospective Multicenter Phase II Trials
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose The optimal short-course chemotherapeutic regimen for rectal cancer has not been clearly defined until now. KROG 10-01 and KROG 11-02 prospective trials investigated the efficacy and safety of 1- and 2-week chemoradiotherapy (CRT), respectively. Materials and Methods Patients eligible for KROG 10-01 and KROG 11-02 involved those with clinical T3-4N0-2M0 rectal cancers. They received preoperative CRT and total mesorectal excision. Patients in KROG 10-01 received radiation of 25 Gy in 5 fractions during 1 week with 5-fluorouracil/leucovorin. Patients in KROG 11-02 received radiation of 33 Gy in 10 fractions for 2 weeks with oral capecitabine. Results A total of 150 patients consisting of 70 patients from KROG 10-01 and 80 patients from KROG 11-02 were collectively analyzed. With a median follow-up time of 89.2 months, the 5-year overall survival rate was 86.5% in 1-week CRT and 85.3% in 2-week CRT (p=0.841). The 5-year recurrence-free survival rate was 83.5% in 1-week CRT and 77.1% in 2-week CRT (p=0.448). One patient (1.4%) in 1-week CRT and 11 patients (13.8%) in 2-week CRT exhibited pathologic complete regression (ypT0N0M0) after radiotherapy (p=0.006). One-week CRT had significantly higher acute hematologic (12.8% vs. 3.8%, p=0.040) and nonhematologic (38.6% vs. 16.3%, p=0.002) toxicity than 2-week CRT. Conclusion Both 1- and 2-week schedules of CRT showed favorable survival outcomes after 7 years of follow-up. But, 2-week course achieved more increased tumor response and decreased acute toxicity than 1-week course.
Abstract
Purpose The optimal short-course chemotherapeutic regimen for rectal cancer has not been clearly defined until now. KROG 10-01 and KROG 11-02 prospective trials investigated the efficacy and safety of 1- and 2-week chemoradiotherapy (CRT), respectively. Materials and Methods Patients eligible for KROG 10-01 and KROG 11-02 involved those with clinical T3-4N0-2M0 rectal cancers. They received preoperative CRT and total mesorectal excision. Patients in KROG 10-01 received radiation of 25 Gy in 5 fractions during 1 week with 5-fluorouracil/leucovorin. Patients in KROG 11-02 received radiation of 33 Gy in 10 fractions for 2 weeks with oral capecitabine. Results A total of 150 patients consisting of 70 patients from KROG 10-01 and 80 patients from KROG 11-02 were collectively analyzed. With a median follow-up time of 89.2 months, the 5-year overall survival rate was 86.5% in 1-week CRT and 85.3% in 2-week CRT (p=0.841). The 5-year recurrence-free survival rate was 83.5% in 1-week CRT and 77.1% in 2-week CRT (p=0.448). One patient (1.4%) in 1-week CRT and 11 patients (13.8%) in 2-week CRT exhibited pathologic complete regression (ypT0N0M0) after radiotherapy (p=0.006). One-week CRT had significantly higher acute hematologic (12.8% vs. 3.8%, p=0.040) and nonhematologic (38.6% vs. 16.3%, p=0.002) toxicity than 2-week CRT. Conclusion Both 1- and 2-week schedules of CRT showed favorable survival outcomes after 7 years of follow-up. But, 2-week course achieved more increased tumor response and decreased acute toxicity than 1-week course.
참고문헌 (30)
- Sauer R, "Preoperative versus postoperative chemoradiotherapy for rectal cancer", N Engl J Med, 351, pp.1731~1740 (2004)
- Gerard JP, "Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers : results of FFCD 9203", J Clin Oncol, 24, pp.4620~4625 (2006)
- Roh MS, "Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum : NSABP R-03", J Clin Oncol, 27, pp.5124~5130 (2009)
- Folkesson J, "Swedish Rectal Cancer Trial : long lasting benefits from radiotherapy on survival and local recurrence rate", J Clin Oncol, 23, pp.5644~5650 (2005)
- You YN, "The American Society of Colon and Rectal Surgeons clinical practice guidelines for the management of rectal cancer", Dis Colon Rectum, 63, pp.1191~1222 (2020)
- Glynne-Jones R, "Rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up", Ann Oncol, 28, pp.iv22~iv40 (2017)
- Benson AB, "Rectal cancer, version 2. 2018, NCCN clinical practice guidelines in oncology", J Natl Compr Canc Netw, 16, pp.874~901 (2018)
- Bujko K, "Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer", Br J Surg, 93, pp.1215~1223 (2006)
- Erlandsson J, "Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer(Stockholm III) : a multicentre, randomised, non-blinded, phase 3, non-inferiority trial", Lancet Oncol, 18, pp.336~346 (2017)
- Kairevice L, "Preoperative long-course chemoradiotherapy plus adjuvant chemotherapy versus short-course radiotherapy without adjuvant chemotherapy both with delayed surgery for stage II-III resectable rectal cancer : 5-Year survival data of a randomized controlled trial", Medicina(Kaunas), 53, pp.150~158 (2017)
- Ngan SY, "Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer : Trans-Tasman Radiation Oncology Group trial 01. 04", J Clin Oncol, 30, pp.3827~3833 (2012)
- Bosset JF, "Chemotherapy with preoperative radiotherapy in rectal cancer", N Engl J Med, 355, pp.1114~1123 (2006)
- Boulis-Wassif S, "Final results of a randomized trial on the treatment of rectal cancer with preoperative radiotherapy alone or in combination with 5-fluorouracil, followed by radical surgery. Trial of the European Organization on Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group", Cancer, 53, pp.1811~1818 (1984)
- Yeo SG, "Preoperative short-course concurrent chemoradiation therapy followed by delayed surgery for locally advanced rectal cancer : a phase 2 multicenter study(KROG 10-01)", Int J Radiat Oncol Biol Phys, 86, pp.34~39 (2013)
- Lee JH, "Two-week course of preoperative chemoradiotherapy followed by delayed surgery for rectal cancer : a phase II multi-institutional clinical trial(KROG 11-02)", Radiother Oncol, 110, pp.150~154 (2014)
- Koeck J, "Small bowel protection in IMRT for rectal cancer : a dosimetric study on supine vs. prone position", Strahlenther Onkol, 193, pp.578~588 (2017)
- White R, "Reduced dose to small bowel with the prone position and a belly board versus the supine position in neoadjuvant 3D conformal radiotherapy for rectal adenocarcinoma", J Med Radiat Sci, 64, pp.120~124 (2017)
- Dworak O, "Pathological features of rectal cancer after preoperative radiochemotherapy", Int J Colorectal Dis, 12, pp.19~23 (1997)
- Wagman R, "Sphincter preservation in rectal cancer with preoperative radiation therapy and coloanal anastomosis : long term follow-up", Int J Radiat Oncol Biol Phys, 42, pp.51~57 (1998)
- Wang X, "Preoperative short-course radiotherapy and long-course radiochemotherapy for locally advanced rectal cancer : meta-analysis with trial sequential analysis of long-term survival data", PLoS One, 13, pp.e0200142~ (2018)
- Ansari N, "Acute adverse events and postoperative complications in a randomized trial of preoperative short-course radiotherapy versus long-course chemoradiotherapy for T3 adenocarcinoma of the rectum : Trans-Tasman Radiation Oncology Group Trial(TROG 01. 04)", Ann Surg, 265, pp.882~888 (2017)
- Liu SX, "Short-course versus long-course preoperative radiotherapy plus delayed surgery in the treatment of rectal cancer : a meta-analysis", Asian Pac J Cancer Prev, 16, pp.5755~5762 (2015)
- Zhou ZR, "Short-course preoperative radiotherapy with immediate surgery versus long-course chemoradiation with delayed surgery in the treatment of rectal cancer : a systematic review and meta-analysis", Surg Oncol, 23, pp.211~221 (2014)
- Dapper H, "Impact of VMAT-IMRT compared to 3D conformal radiotherapy on anal sphincter dose distribution in neoadjuvant chemoradiation of rectal cancer", Radiat Oncol, 13, pp.237~ (2018)
- Reddy Abhinav V., "Impact of somatic mutations on clinical and pathologic outcomes in borderline resectable and locally advanced pancreatic cancer treated with neoadjuvant chemotherapy and stereotactic body radiotherapy followed by surgical resection", Radiation oncology journal, 39(4), pp.304~314 (2021), 대한방사선종양학회[DOI]
- Chan AK, "Preoperative capecitabine and pelvic radiation in locally advanced rectal cancer--is it equivalent to 5-FU infusion plus leucovorin and radiotherapy?", Int J Radiat Oncol Biol Phys, 76, pp.1413~1419 (2010)
- Desai SP, "A phase II study of preoperative capecitabine and radiation therapy in patients with rectal cancer", Am J Clin Oncol, 30, pp.340~345 (2007)
- Hofheinz RD, "Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer : a randomised, multicentre, non-inferiority, phase 3 trial", Lancet Oncol, 13, pp.579~588 (2012)
- 송진호, "Preoperative chemoradiotherapy versus postoperative chemoradiotherapy for stage II–III resectable rectal cancer: a meta-analysis of randomized controlled trials", Radiation oncology journal, 35(3), pp.198~207 (2017), 대한방사선종양학회
- Ngan SY, "A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer", Br J Cancer, 91, pp.1019~1024 (2004)